Overview

Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

Status:
Completed
Trial end date:
2010-12-08
Target enrollment:
Participant gender:
Summary
This study will look at the safety of a drug used in participants who have had hepatic encephalopathy (HE) in the past.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Treatments:
Rifaximin